Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroidal therapy

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 3 SUPPL., 1999, Pages

  Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atopy; Corticosteroid; Eczema; FK 506

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN; TACROLIMUS;

ATOPIC DERMATITIS; ATOPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; ECZEMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; PEDIATRICS; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SKIN ATROPHY; SKIN INFLAMMATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; HUMANS; OINTMENTS; TACROLIMUS;

EID: 0032879113     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70055-2     Document Type: Article

References (30)

1. Umeki S. Allergic cycle: relationships between asthma, allergic rhinitis, and atopic dermatitis. J Asthma 1994;31:19-26.
2. Schultz Larsen F. Atopic dermatitis: an increasing problem. Pediatr Allergy Immunol 1996;7(suppl):51-3.
3. Sampson HA. Atopic dermatitis. Ann Allergy 1992;69:469-81.
4. Hanifin JM. Assembling the puzzle pieces in atopic inflammation. Arch Dermatol 1996;132:1230-2.
5. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998;351:1715-21.
6. Linde YW. Dry skin in atopic dermatitis. Acta Derm Venereol 1992;177(suppl):9-13.
7. Smith EW. Four decades of topical corticosteroid assessment. Curr Probl Dermatol 1995;22:124-31.
8. Lubach D, Rath J, Kietzmann M. Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. Dermatology 1995;190:51-5.
9. Pierard GE, Pierard-Franchimont C, Ben Mosbah T, Arrese Estrada J. Adverse effects of topical corticosteroids. Acta Derm Venereol 1989;151(suppl):26-30.
10. La Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994;73:117-22.
11. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis: a multi-crossover-designed study. Allergy 1994;49:22-6.
12. Rothe MJ, Grant-Kels JM. Atopic dermatitis: an update. J Am Acad Dermatol 1996;35:1-13.
13. de Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Dermato-Venereologica. Supplementum. 1989;144:136-8.
14. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991;71:452-4.
15. Thompson AW, Aldridge RD, Sewell HF. Topical cyclosporin in alopecia areata and nickel contact dermatitis. Lancet 1986;2:971-2.
16. Sawada S, Suzuki G, Kawase Y, Takaku F Novel immunosuppressive agent, FK506, in vitro effects on cloned T-cell activation. J Immunol 1987;139:1797-1803.
17. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-75.
18. Jordan ML, Shapiro R, Vivas CA, Scantlebury V, Gritsch HA, Ellis D, et al. The use of tacrolimus in renal transplantation. World J Urol 1996;14:239-42.
19. Lawrence ED. Tacrolimus (FK506): experience in dermatology. Dermatol Ther 1998;5:74-84.
20. Kelly PA, Burckart GL, Venkataramana R. Tacrolimus: a new immunosuppressive agent. Am J Heath Syst Pharm 1995;52:1521-1535.
21. Mori A, Suko M, Nishizaki Y, Kaminuma O, Matsuzaki G, Ito K, et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994;104(suppl 1):32-5.
22. de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992;99:723-8.
23. Eberlein-Konig B, Michel G, Ruzicka T, Przybilla B. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res 1997;289:606-8.
24. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396-8.
25. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344:883.
26. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995;133:494-6.
27. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998;38:69-76.
28. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996;348:1240-1.
29. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816-21.
30. Boguniewicz A, Fielder VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM. A randomised, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102:637-44.